These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7926138)

  • 1. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study.
    Vercellini P; Sacerdote P; Trespidi L; Manfredi B; Panerai AE; Crosignani PG
    Fertil Steril; 1994 Nov; 62(5):938-42. PubMed ID: 7926138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
    Vercellini P; Vendola N; Colombo A; Passadore C; Trespidi L; Crosignani PG
    Gynecol Obstet Invest; 1992; 34(2):102-4. PubMed ID: 1398260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
    Melis GB; Gambacciani M; Cagnacci A; Paoletti AM; Mais V; Fioretti P
    Obstet Gynecol; 1988 Nov; 72(5):688-92. PubMed ID: 3140150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride].
    Wesel S; Bosuma WB
    Sem Hop; 1983 Mar; 59(9):596-9. PubMed ID: 6304907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter comparison of veralipride versus placebo in the vasomotor flushes of menopause. An evaluation of the prolonged effect].
    Boulot P; Viala JL
    Rev Fr Gynecol Obstet; 1988 Dec; 83(12):823-7. PubMed ID: 3064254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome].
    De Cecco L; Venturini PL; Alibrandi MP; Grondona AL; Morano S; Penna L; Campanella G; Ragni N
    Rev Fr Gynecol Obstet; 1985 Feb; 80(3):152-5. PubMed ID: 3922034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes.
    Wesel S; Bourguignon RP; Bosuma WB
    Curr Med Res Opin; 1984; 8(10):696-700. PubMed ID: 6327190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of the action of a new molecule, veralipride, on menopausal psychofunctional disorders (author's transl)].
    Delanian L
    Sem Hop; 1980 Oct; 56(37-38):1468-70. PubMed ID: 6254163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes.
    Carretti N; Florio P; Reis FM; Comai S; Bertazzo A; Petraglia F
    Climacteric; 2010 Apr; 13(2):141-6. PubMed ID: 20082603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-hormonal therapy for menopausal disorders: results of a multicentric double-blind trial (author's transl)].
    Linquette M; Rivière J; Vague J
    Sem Hop; 1980 Oct; 56(37-38):1445-8. PubMed ID: 6254159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of veralipride in menopausal sudden flushes (author's transl)].
    Wesel S; L'Hermite M
    Sem Hop; 1980 Oct; 56(37-38):1465-7. PubMed ID: 6254162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veralipride: alternative antidopaminergic treatment for menopausal symptoms.
    David A; Don R; Tajchner G; Weissglas L
    Am J Obstet Gynecol; 1988 May; 158(5):1107-15. PubMed ID: 2967034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of veralipride.
    De Leo V; Morgante G; Musacchio MC; Faldini E; Delia A; Petraglia F
    Expert Opin Drug Saf; 2006 Sep; 5(5):695-701. PubMed ID: 16907659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of an novel molecule, veralipride, in the treatment of menopausal disorders].
    Grall JY
    Sem Hop; 1982 Nov; 58(43):2535-7. PubMed ID: 6297046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of menopausal hot flushes with a nonhormonal medication, veralipride].
    Marzolf G; Eberst B; Aerts A; Lecornu C; Mark J; Gandar R
    Sem Hop; 1982 Nov; 58(41):2382-4. PubMed ID: 6297023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized, placebo-controlled study.
    Neele SJ; Evertz R; Genazzani AR; Luisi M; Netelenbos C
    Fertil Steril; 2002 Jun; 77(6):1110-7. PubMed ID: 12057714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.
    Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
    Gynecol Endocrinol; 2004 Apr; 18(4):194-8. PubMed ID: 15293890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of hot flashes due to menopause. Comparative study of two drugs (author's transl)].
    Renaud R; Macler J
    Sem Hop; 1981 Feb 18-25; 57(7-8):353-5. PubMed ID: 6261369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes.
    Zichella L; Falaschi P; Fioretti P; Melis GB; Cagnacci A; Gambacciani M; Mancini S
    Maturitas; 1986 Oct; 8(3):229-37. PubMed ID: 3784919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
    Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
    Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.